## Contents

**REVIEW**

4567  Current understanding of the metabolism of micronutrients in chronic alcoholic liver disease

\[ Wu J, Meng QH \]

**MINIREVIEWS**

4579  COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract


**ORIGINAL ARTICLE**

### Basic Study

4589  Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma

\[ Xiao JB, Weng JY, Hu YY, Deng GL, Wan XJ \]

### Case Control Study

4607  Establishment of a pattern recognition metabolomics model for the diagnosis of hepatocellular carcinoma

\[ Zhou PC, Sun LQ, Shao L, Yi LZ, Li N, Fan XG \]

### Retrospective Cohort Study

4624  Impact of interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients


### Retrospective Study

4639  Monocyte-to-lymphocyte ratio as a prognostic factor in peripheral whole blood samples of colorectal cancer patients

\[ Jakubowska K, Koda M, Grudzińska M, Kańczuga-Koda L, Famulski W \]

4656  Clinical and prognostic significance of CC chemokine receptor type 8 protein expression in gastrointestinal stromal tumors

\[ Li HL, Wang LH, Hu YL, Feng Y, Li XH, Liu YF, Li P, Mao QS, Xue WJ \]

4669  Initial experience of single-incision plus one port left-side approach totally laparoscopic distal gastrectomy with uncut Roux-en-Y reconstruction

\[ Zhou W, Dong CZ, Zang YF, Xue Y, Zhou XG, Wang Y, Ding YL \]

4680  Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study

Clinical characteristics and risk factors for liver injury in COVID-19 patients in Wuhan


**Observational Study**

Mucosal-associated invariant T cells in hepatitis B virus-related liver failure

Xue H, Li H, Ju LL, Han XD, Cheng TC, Luo X, Chen L, Shao JG, She YJ, Bian ZL

**SYSTEMATIC REVIEWS**

Risk of malignancy in Caroli disease and syndrome: A systematic review

Fahrner R, Dennler SG, Inderbitzin D
ABOUT COVER
Editorial board member of World Journal of Gastroenterology, Dr. Tatsuo Kanda received an MD from the Niigata University School of Medicine (Japan) in 1991 and a PhD from the Graduate School of Medicine at Chiba University (Japan) in 1999. He then undertook post-doctoral training in the Departments of Pathology and Internal Medicine at Saint Louis University School of Medicine (United States) under the mentorship of Prof. Ratna B. Ray and Prof. Ranjit Ray, respectively. He returned to Japan and became an Associate Professor in the Department of Gastroenterology and Nephrology at Chiba University Graduate School of Medicine in 2008. In his current roles as Associate Professor and Clinical Professor in the Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine at Itabashi-ku, Tokyo, Japan, he performs clinical and basic research on hepatic and pancreatic diseases. (L-Editor: Filipodia)

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as ScSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for WJG as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Jie Ma; Production Department Director: Xiang Li; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS
http://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE
August 21, 2020

COPYRIGHT
© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Observational Study

Mucosal-associated invariant T cells in hepatitis B virus-related liver failure

Hong Xue, Han Li, Lin-Ling Ju, Xu-Dong Han, Tiao-Chun Cheng, Xi Luo, Lin Chen, Jian-Guo Shao, Yong-Jun She, Zhao-Lian Bian

ORCID number: Hong Xue 0000-0002-2271-2362; Han Li 0000-0003-3694-1120; Lin-Ling Ju 0000-0002-9541-0533; Xu-Dong Han 0000-0001-9733-678X; Tiao-Chun Cheng 0000-0002-9167-219X; Xi Luo 0000-0002-7288-6870; Lin Chen 0000-0002-1108-4735; Jian-Guo Shao 0000-0002-4840-5512; Yong-Jun She 0000-0001-7099-7449; Zhao-Lian Bian 0000-0002-0802-6497.

Author contributions: Xue H, Li H and Ju L-L contributed equally to this work; Xue H and Ju L-L performed the flow cytometry analysis; Li H and Cheng T-C wrote the manuscript; Luo X and Chen L performed the statistical analysis; Han X-D, Shao J-G and She Y-J revised the manuscript; Bian Z-L designed the study and revised the manuscript.

Supported by National Natural Science Foundation of China, No. 81600449; Nantong Science and Technology Bureau, No. MS22018007, No. MSZ18130, and No. JCZ18036; Six Peak Talents in Jiangsu Province, No. YY-177; Project of Jiangsu Province Youth Medical Talent Development, No. QYRC2016400; and Project of Nantong Youth Medical Talent Development, No. 05.

Abstract

BACKGROUND
Liver failure has high mortality and poor prognosis, and establishing new reliable markers for predicting its prognosis is necessary. Mucosal-associated invariant T (MAIT) cells are a novel population of innate-like lymphocytes involved in inflammatory liver disease, and their potential role in liver failure remains unclear.

AIM
To investigate alteration of circulating MAIT cells and assess its prognostic value in patients with hepatitis B virus (HBV)-related liver failure.

METHODS

Institutional review board

Hong Xue, Department of Liver Diseases, Nantong Third People’s Hospital, Nantong University, Nantong 226006, Jiangsu Province, China

Han Li, Tiao-Chun Cheng, Medical School of Nantong University, Nantong 226006, Jiangsu Province, China

Lin-Ling Ju, Xi Luo, Lin Chen, Jian-Guo Shao, Zhao-Lian Bian, Nantong Institute of Liver Diseases, Nantong Third People’s Hospital, Nantong University, Nantong 226006, Jiangsu Province, China

Xu-Dong Han, Department of Critical Care Medicine, Nantong Third People’s Hospital, Nantong University, Nantong 226006, Jiangsu Province, China

Jian-Guo Shao, Zhao-Lian Bian, Department of Gastroenterology and Hepatology, Nantong Third People’s Hospital, Nantong University, Nantong 226006, Jiangsu Province, China

Yong-Jun She, Department of Anesthesiology, Nantong Third People’s Hospital, Nantong University, Nantong 226006, Jiangsu Province, China

Corresponding author: Zhao-Lian Bian, MD, PhD, Associate Professor, Department of Gastroenterology and Hepatology, Nantong Third People’s Hospital, Nantong University, No. 60 Middle Qingnian Road, Nantong 226006, Jiangsu Province, China. bianzhaolian1998@163.com
Liver failure is a life-threatening clinical syndrome caused by multiple factors, leading to severe impairment or decompensation of synthesis, detoxification, metabolism and biotransformation, mainly presenting a group of clinical manifestations such as jaundice, coagulopathy, heporenal syndrome, hepatic encephalopathy and ascites[1]. Liver failure is a devastating disease with high morbidity and mortality. In China, the main cause of liver failure is hepatitis B virus (HBV) infection[3]. It develops rapidly and has extremely poor prognosis[3], so judging the severity and predicting the prognosis of liver failure are important.

Although there are various indicators or scoring systems for assessing the severity and prognosis in patients with liver failure, such as alanine aminotransferase, aspartate transaminase, prothrombin activity (PTA), model for end-stage liver disease (MELD) score and MELD-sodium (MELD-Na) score, these conventional scoring systems do not include extrahepatic organ failure and systemic inflammation, which
limits their prognostic accuracy in liver failure. Because of the absence of gold standard markers for prognosis of liver failure\(^8\), it is important to find additional reliable markers for predicting prognosis, enabling patients with poor prognosis to receive liver transplantation earlier to improve survival.

Mucosal-associated invariant T (MAIT) cells, the most abundant T cell subset that responds to bacteria in humans, are characterized by the invariant T-cell receptor (TCR) chain, Vα7.2-Jα33, and show high expression of the natural killer cell marker CD161. MAIT cells are found throughout the body, especially in human blood and liver. MAIT cells mediate protective immunity against infection and are increasingly being recognized for their importance in microbial immunity. As one of the largest T cell populations in the human liver, MAIT cells act as a “firewall” and play an important role in the front line of defense in the liver. MAIT cells are involved in the development of various liver diseases\(^9\). They can be activated in an antigen- and cytokine-dependent manner in chronic inflammatory liver disease\(^10\). Recent studies have reported that MAIT cells in blood and liver in patients with chronic liver inflammatory disease, including alcoholic or nonalcoholic fatty liver disease, cirrhosis, autoimmune liver disease and chronic hepatitis C and D\(^11\) are decreased dramatically, but the phenotype of MAIT cells is more activated or shows functional impairment in different types of liver disease. However, circulating MAIT cells are not reversed after direct-acting-antiviral-mediated clearance of hepatitis C virus (HCV)\(^12\). Further studies explored the mechanism of MAIT cell involvement in liver inflammatory disease, including promoting liver inflammation and fibrosis dependent on monocyte-derived macrophages, maintaining intestinal mucosal permeability\(^13\) and reacting with biliary epithelium and liver B cells\(^14\). From previous studies, tumor-infiltrating MAIT cells are a prognostic factor for hepatocellular carcinoma\(^15\) and colorectal cancer\(^16\). Circulating MAIT cells are also a biomarker for response to standard treatment in primary biliary cholangitis\(^17\) and immune thrombocytopenia\(^18\) and prognosis in cervical cancer\(^19\).

There are various reports about the frequency of circulating MAIT cells in patients with HBV infection. Yong and colleagues found that frequency of MAIT cells was decreased, presenting dysfunction in chronic hepatitis B (CHB) infection\(^20\). Boeijen et al\(^21\) reported that MAIT cells were more activated and could be reversed by antiviral therapy, but the frequency of circulating MAIT cells was not decreased in CHB infection. In acute liver failure, it was reported that hepatic MAIT cells accumulated in the parenchyma, but the circulating MAIT cells were not detected and the etiology of liver failure was not revealed\(^22\). In China, the hepatitis B infection is the major cause of liver failure and T-cell-mediated immune injury plays a critical role in the pathogenesis of HBV-related liver failure. In this paper, we evaluated the change of circulating MAIT cells and its prognostic value in patients with HBV-related liver failure and explored the possible mechanism.

MATERIALS AND METHODS

Patient data
A total of 173 participants were enrolled, including 40 healthy controls, 48 CHB patients and 85 liver failure patients. We excluded 30 non-HBV related liver failure patients and enrolled 55 HBV related liver failure patients (Figure 1). Liver failure was diagnosed and treated according to the Guidelines in China\(^23\). CHB patients \((n = 48)\) were diagnosed according to the American Association for the Study of Liver Disease 2018 guidelines for hepatitis B\(^24\). HBV-related liver failure \((n = 55)\) was defined as liver failure accompanied with HBV activity, which was considered as HBV-DNA positive, and without other causes of liver failure. None of the patients in the CHB and HBV-related liver failure groups received any antiviral therapy before the study, or antiviral drugs were discontinued for >6 mo before the study. The research process is shown in a flow chart (Figure 1), and the demographic and clinical characteristics of the participants are presented in Table 1. This study was approved by the Ethical Committee of Nantong Third People’s Hospital, Nantong University, and patients gave signed informed consent.

Peripheral blood mononuclear cells isolation
Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation with GE Healthcare Ficoll-Paque PLUS Media (Thermo Scientific, Rosemont, IL, United States) as our previous study described\(^25\). Five milliliters of peripheral blood was centrifuged for 10 min at 300 x g at 20 °C. The buffy coat interphase layer was
Table 1 Characteristics of healthy controls and chronic hepatitis B and hepatitis B virus-related liver failure patients

<table>
<thead>
<tr>
<th>Clinical parameters</th>
<th>HC</th>
<th>CHB</th>
<th>HBV-related liver failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>40</td>
<td>48</td>
<td>55</td>
</tr>
<tr>
<td>Age in yr</td>
<td>47.05 ± 14.70</td>
<td>41.63 ± 13.08</td>
<td>47.89 ± 11.04</td>
</tr>
<tr>
<td>Male, n</td>
<td>24</td>
<td>27</td>
<td>37</td>
</tr>
<tr>
<td>ALT in U/L</td>
<td>16.55 ± 5.43</td>
<td>327.52 ± 312.57</td>
<td>549.60 ± 686.13</td>
</tr>
<tr>
<td>AST in U/L</td>
<td>22.95 ± 5.70</td>
<td>176.58 ± 208.19</td>
<td>487.55 ± 571.49</td>
</tr>
<tr>
<td>Total bilirubin in μmol/L</td>
<td>12.48 ± 3.23</td>
<td>25.65 ± 43.43</td>
<td>302.52 ± 144.84</td>
</tr>
<tr>
<td>Albumin in g/L</td>
<td>42.98 ± 2.32</td>
<td>42.36 ± 3.99</td>
<td>31.01 ± 4.06</td>
</tr>
<tr>
<td>Prealbumin in mg/L</td>
<td>109.17 ± 68.43</td>
<td>174.09 ± 81.47</td>
<td>174.09 ± 81.47</td>
</tr>
<tr>
<td>Cholinesterase in U/L</td>
<td>6536.11 ± 2543.80</td>
<td>3214.65 ± 1663.35</td>
<td>3214.65 ± 1663.35</td>
</tr>
<tr>
<td>Prothrombin time in s</td>
<td>NA</td>
<td>NA</td>
<td>25.44 ± 8.30</td>
</tr>
<tr>
<td>International normalized ratio</td>
<td>NA</td>
<td>NA</td>
<td>2.22 ± 0.74</td>
</tr>
<tr>
<td>Prothrombin activity as %</td>
<td>NA</td>
<td>NA</td>
<td>29.87 ± 9.09</td>
</tr>
<tr>
<td>Leucocyte as × 10^9/L</td>
<td>5.77 ± 1.60</td>
<td>5.01 ± 1.30</td>
<td>6.74 ± 4.18</td>
</tr>
<tr>
<td>Lymphocyte number as × 10^9/L</td>
<td>2.64 ± 0.73</td>
<td>1.70 ± 0.60</td>
<td>3.08 ± 5.40</td>
</tr>
<tr>
<td>Blood platelets as × 10^9/L</td>
<td>194.68 ± 41.53</td>
<td>157.52 ± 67.53</td>
<td>97.96 ± 52.06</td>
</tr>
<tr>
<td>Creatinine in μmol/L</td>
<td>63.08 ± 13.24</td>
<td>96.69 ± 123.50</td>
<td>96.69 ± 123.50</td>
</tr>
<tr>
<td>hs-CRP in mg/dL</td>
<td>NA</td>
<td>NA</td>
<td>20.04 ± 29.97</td>
</tr>
<tr>
<td>Log HBV DNA in IU/mL</td>
<td>6.81 ± 1.33</td>
<td>5.27 ± 1.79</td>
<td>5.27 ± 1.79</td>
</tr>
</tbody>
</table>

All data are presented as mean ± SD.

*P < 0.0001 vs HC.

*P < 0.05,

*P < 0.01,

*P < 0.001,

*P < 0.0001. vs CHB. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CHB: Chronic hepatitis B; HBV: Hepatitis B virus; HC: Healthy controls; hs-CRP: Hypersensitive C-reactive protein; NA: Not applicable.

Flow cytometry

PBMCs were stained with combinations of the following antibodies: anti-TCRα7.2-phycocerythrin (PE; BD Biosciences, Franklin Lakes, NJ, United States), anti-CD161-allophycocyanin (APC; BD Biosciences) and anti-CD5-fluorescein isothiocyanate (FITC; BD Biosciences). Flow cytometry was performed using FACS Calibur (BD Biosciences). Data were analyzed using FlowJo software (Tree Star, San Carlos, CA, United States).

Plasma cytokine detection

Interleukin (IL)-7, IL-12p70, IL-18 and interferon (IFN)-α were measured using the Human Magnetic Luminex Assay Kit (R&D Systems, Minneapolis, MN, United States) in human plasma samples. The results were read and analyzed on Luminex MAGPIX Instrument System (Luminex, Austin, TX, United States).

Statistical analysis

All data are presented as mean ± standard deviation. Analysis in patients before and
RESULTS

Characteristics of healthy controls and patients with CHB and HBV-related liver failure

The detailed clinical characteristics of the participants, including healthy controls (HCs) (n = 40), patients with CHB (n = 48) and patients with HBV-related liver failure (n = 55), are presented in Table 1. There were no differences in age and gender between patients with CHB, patients with HBV-related liver failure and HCs. The levels of alanine aminotransferase (HBV-related liver failure vs HC: 549.60 ± 686.13 vs 16.55 ± 5.43, P < 0.0001; HBV-related liver failure vs CHB: 549.60 ± 686.13 vs 327.52 ± 312.57, P
Circulating MAIT cells were dramatically decreased in HBV-related liver failure

Circulating MAIT cells were defined as CD3+/CD161+ TCR Vα7.2+. The strategy for flow cytometry of MAIT cells is illustrated in Figure 2A. We counted the percentage of circulating MAIT cells in CD3+ T cells and the number of circulating MAIT cells in 106 PBMCs in patients with HBV-related liver failure, patients with CHB and HCs. The percentage and number of circulating MAIT cells in HBV-related liver failure patients (percentage: 2.00 ± 1.22 vs 5.19 ± 1.27%, P < 0.0001; number: 5.47 ± 4.93 vs 84.43 ± 19.59, P < 0.0001) and CHB (percentage: 3.59 ± 0.87 vs 5.19 ± 1.27%, P < 0.0001; number: 48.26 ± 15.45 vs 84.43 ± 19.59, P < 0.0001) were significantly lower than in HCs. Circulating MAIT cells exhibited a significant decrease in HBV-related liver failure patients compared with CHB patients (percentage: 2.00 ± 1.22 vs 3.59 ± 0.87%, P < 0.0001; number: 5.47 ± 4.93 vs 48.26 ± 15.45, P < 0.0001) (Figure 2B and C).

Quantity of circulating MAIT cells was associated with severity in HBV-related liver failure patients

Patients with HBV-related liver failure were divided into two groups according to the level of PTA: Early stage (n = 28) and middle/late stage (n = 27). The percentage and number of circulating MAIT cells were analyzed. A significant reduction in percentage (Figure 3A) and number (Figure 3B) of MAIT cells was found in patients with middle/late-stage disease compared with early stage. We analyzed the correlation between MAIT cells and parameters in Table 1, and data showed that PTA was not associated with percentage of MAIT cells (Figure 3C) but correlated with MAIT cell counts (P = 0.0321) (Figure 3D). Other parameters were not associated with the percentage or number of circulating MAIT cells in HBV-related liver failure (data not shown).

Partial recovery of circulating MAIT cells in surviving HBV-related liver failure patients

We collected PBMCs from 18 patients before and after therapy, including 13 surviving patients and five patients who died or received liver transplantation. The indicated time for post-therapy was defined as the endpoint of conservative treatment in patients who were cured, died or received liver transplantation. We analyzed the variation in percentage and number of circulating MAIT cells in these patients. In the survival group (n = 13), circulating MAIT cells were partially recovered after disease improvement not only in percentage (4.01 ± 1.21 vs 2.04 ± 0.95%, P < 0.0001) (Figure 4A), but also in cell count (17.24 ± 8.56 vs 7.41 ± 4.99, P < 0.0001) (Figure 4B) and they were still lower than in HCs, especially MAIT cell count (Figure 4A and B). However, the level of circulating MAIT cells showed no difference in before and after conservative treatment among those who died and received liver transplantation (n = 5) (Figure 4C and D).

Lower circulating MAIT cells indicated poor prognosis in HBV-related liver failure

Based on the outcome, we divided the HBV-related liver failure patients into the survival group (n = 32) and died/liver transplanted group (n = 23). Comparison of MAIT cells between them showed that the proportion (2.29 ± 1.01 vs 1.58 ± 1.38%, P < 0.05) (Figure 5A) and number of circulating MAIT cells (7.30 ± 5.70 vs 2.94 ± 1.47, P < 0.001) (Figure 5B) were significantly higher in the survival group than the died/LT group. We followed up the 55 HBV-related liver failure patients for 2-90 d, then the patients were divided into two groups, low expression (n = 27) and high expression (n = 28) of MAIT cells based on median proportion or cell counts of circulating MAIT cells. The Kaplan–Meier curve showed that lower expression of circulating MAIT cells (both percentage and cell count) predicted poor overall survival in HBV-related liver failure patients (P < 0.01) (Figure 5C and D). We compared the prognostic value of
Figure 2 Circulating mucosal-associated invariant T cells were dramatically decreased in hepatitis B virus-related liver failure. A: The strategy for flow cytometry of mucosal-associated invariant T (MAIT) cells; B: The percentage of circulating MAIT cells in healthy controls (HC, n = 40), chronic hepatitis B (CHB, n = 48) patients and hepatitis B virus (HBV)-related liver failure (LF) patients (n = 55); C: Circulating MAIT cell count in 10^6 peripheral blood mononuclear cells in HCs and CHB and HBV-related liver failure patients. *P < 0.0001.

MELD score with MAIT cells (proportion and counts) and showed using receiver operating characteristic curve data that the proportion of MAIT cells can better predict the prognosis of HBV-related liver failure patients than MELD score and MAIT cell counts (Figure 6).

Plasma levels of IL-12 and IL-18 were increased in patients with HBV-related liver failure

It is well recognized that MAIT cells can be activated and exhausted by inflammatory cytokines, including IL-12, IL-18, IL-7 and IFN-α. To explore the possible mechanism of decreased circulating MAIT cells in HBV-related liver failure, we detected these inflammatory cytokines in the plasma of HBV-related liver failure patients (n = 46) and HCs (n = 40). The level of IL-12 (20.26 ± 5.42 pg/mL vs 17.76 ± 2.79 pg/mL, P = 0.01) and IL-18 (1470.05 ± 1525.38 pg/mL vs 362.99 ± 109.64 pg/mL, P < 0.0001) were increased in HBV-related liver failure patients compared to HCs (Figure 7A and B). However, there was no difference in IL-7 and IFN-α between the
Figure 3  Quantity of circulating mucosal-associated invariant T cells was associated with severity of hepatitis B virus-related liver failure. A, B: The percentage (A) and number (B) of circulating mucosal-associated invariant T (MAIT) cells in early- (n = 28) and middle/late-stage (n = 27) hepatitis B virus (HBV)-related liver failure; C, D: Correlation between prothrombin activity (PTA) and percentage (C) or number (D) of circulating MAIT cells in patients with HBV-related liver failure. *P < 0.05, **P < 0.01. PBMC: Peripheral blood mononuclear cell. NS: No significance.

two groups (Figure 7C and D). These data indicated that IL-12 and IL-18 contributed to the depletion of circulating MAIT cells in HBV-related liver failure patients.

DISCUSSION

In previous studies, MAIT cells were reported in multiple tissues, including liver, lung, pancreas, female genital mucosa, spleen and lymph nodes\(^\text{[25]}\). They represent about 6% of all CD3\(^+\) T cells in human blood and up to 20% in the lungs. More importantly, MAIT cells account for up to 40% of T cells in the liver\(^\text{[26]}\), which indicates that they play a critical role in liver disease. MAIT cells are involved in many types of immune disorders, including viral\(^\text{[27]}\) and bacterial\(^\text{[28]}\) infections. From further study, we know that MAIT cells recognize microbial metabolites and rapidly respond to pathogens, release cytokines, lyse target cells and promote inflammatory response, including in infectious and noninfectious inflammatory diseases, by secreting Th1 and Th17 cytokines. MAIT cells also play a critical role in liver diseases by promoting hepatitis and fibrosis, maintaining intestinal permeability and responding to biliary epithelium cells and liver B cells. MAIT cells were reported to be activated in patients with cirrhosis and displayed a proinflammatory profile. The profibrogenic functions of MAIT cells suggested that targeting MAIT cells may constitute an attractive antifibrogenic strategy during chronic liver injury. In addition, MAIT cells have antibacterial potency and play a key role as biliary firewall protecting the epithelial
Figure 4  Partial recovery of circulating mucosal-associated invariant T cells in survived hepatitis B virus-related liver failure patients. A, B: The percentage (A) and count (B) of circulating mucosal-associated invariant T (MAIT) cells before and after treatment of surviving patients (n = 13) with hepatitis B virus (HBV)-related liver failure, and in healthy controls (HC) (n = 40); C, D: The percentage (C) and number (D) of MAIT cells in patients (n = 5) who died or underwent liver transplantation in HBV-related liver failure before and after conservative treatment. *P < 0.01, **P < 0.0001. NS: No significance; PBMC: Peripheral blood mononuclear cell.

lining from translocated bacteria. In patients with alcoholic liver disease, the antibacterial potency of MAIT cells are impaired as a consequence of contact with microbial products and microbiota, which results in susceptibility to infection.

The liver is an important immune organ in humans, with unique immune cells. MAIT cells are located around the bile ducts in the portal tracts and can exert antibacterial and antiviral effects. Hegde et al[7] found that circulating MAIT cells were reduced in patients with alcoholic or nonalcoholic fatty liver disease-related cirrhosis. Yong et al.[29] demonstrated that peripheral MAIT cells were significantly decreased in chronic HBV-infected patients. In line with the results above, we discovered that circulating MAIT cells were significantly reduced in patients with CHB. Additionally, we found that circulating MAIT cells were dramatically decreased in HBV-related liver failure compared with CHB. These findings may indicate that HBV-related liver
Figure 5 Lower count of circulating mucosal-associated invariant T cells indicated poor prognosis in hepatitis B virus-related liver failure. A, B: The proportion (A) and number (B) of circulating mucosal-associated invariant T (MAIT) cells in surviving ($n = 32$) and deceased/liver transplanted (LT) ($n = 23$) patients with hepatitis B virus (HBV)-related liver failure; C, D: The Kaplan–Meier curve of HBV-related liver failure patients with low ($n = 27$) and high ($n = 28$) expression of MAIT cells in percentage (C) and count (D). *$P < 0.05$, **$P < 0.001$. PBMC: Peripheral blood mononuclear cell.

Immune responses play a crucial role in the pathogenesis of liver failure, and T-cell-mediated immune responses play a critical role in the pathogenesis of HBV-related acute-on-chronic liver failure (ACLF). The enrichment of MAIT cells in the liver and its anatomical location close to the biliary tract suggest that MAIT cells play an important role in liver immune defense and possibly HBV-related liver failure. A recent study suggested that T-cell-mediated immune response plays a vital role in acute HBV infection and the pathogenesis of HBV-related ACLF, which suggests that T-cell
responses play a crucial role in virus control and immune-mediated liver damage. Another recent study\textsuperscript{32} showed that chronic HBV and HCV infections always lead to T-cell depletion or dysfunction, which results in immune tolerance and viral persistence. The pathogenesis of ACLF is also a dysfunctional immune response caused by systemic inflammation and increased immune cell paralysis.

Böttcher et al\textsuperscript{9} showed that MAIT cells were decreased in peripheral blood and liver tissue in autoimmune immune liver disease and found that intrahepatic MAIT cells tended to decrease with increasing fibrosis stage. They considered that the decrease was related to long-term exposure to cytokines and bacterial antigens, resulting in cell exhaustion. Together with their findings, our data showed a more significant decrease of circulating MAIT cells when the patients’ condition worsened. During the middle/late stage of liver failure, perhaps due to the long-term chronic course, circulating MAIT cells are increasingly depleted and the body mounts a dysfunctional immune response and enters an immunosuppressive state, resulting in viral persistence and aggravated conditions. Given that patients with end-stage chronic liver disease in most cases have at least some degree of malnutrition and decreased protein synthesis, maybe MAIT cells’ decrease is also associated with malnutrition, decreased protein synthesis and the reduction of lymphocytes.

Previous research has suggested that successful antiviral therapy does not restore the frequency of circulating MAIT cells, such as in patients with CHB or HCV or human immunodeficiency virus infection. Bolte and Rehermann\textsuperscript{6} once mentioned that HCV infection leaves a lasting imprint on the MAIT cell population. We discovered that after treatment, the frequency and number of circulating MAIT cells partially recovered when HBV-related liver failure improved. We believe that in different immune environments of diseases, the circulating MAIT cells may undergo different immune processes (including immune exhaustion and chronic immune activation), resulting in different function and behavior of MAIT cells in the systemic circulation. This was an important discovery, and it is worthy of further study to explore the mechanism in patients with HBV-related liver failure.

Shen et al\textsuperscript{31} have mentioned the lack of predictive prognostic biomarkers for hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). Currently, the
Figure 7  Plasma levels of interleukin-12 and interleukin-18 were increased in patients with hepatitis B virus-related liver failure. A-D: Plasma level of interleukin (IL)-12p70 (A), IL-18 (B), IL-7 (C) and interferon-α (D) in healthy controls (HC) (n = 40) and patients with hepatitis B virus (HBV)-related liver failure (n = 46). aP < 0.05; dP < 0.0001. NS: No significance.

predictive scoring systems (including MELD and MELD-Na) for assessing the prognosis of patients with liver failure have defects, such as too complex, low sensitivity and limited application value. The prognosis of liver failure patients is poor. To find an objective, accurate and convenient prognostic marker for clinical application is still urgently needed. Given that the immune response plays a crucial role in the pathogenesis of liver failure, some immune-related prognostic markers appear, such as tumor necrosis factor-α-induced protein-8 like-2[33]. The latter is reported to have a potential role in predicting prognosis in patients with HBV-ACLF by negative regulation of cell-mediated immunity. Also, there were reports that peripheral myeloid-derived suppressor cells[34] and CD8 T cells acted as biomarkers for prognosis in HBV-ACLF. Our data indicate that circulating MAIT cells are an important marker for predicting the prognosis of HBV-related liver failure by showing obvious reduction of MAIT cells in deceased compared to surviving patients and a higher survival rate accompanied by higher expression of MAIT cells. It may be that depletion of MAIT cells leads to immunosuppression, increasing the risk of opportunistic infections, with severe consequences. Therefore, MAIT cells are vital for assessing the prognosis of patients with HBV-related liver failure, and early assessment can help physicians determine earlier which patients should receive liver transplantation and thus improve their prognosis.

Previous studies have shown that the exhaustion of blood MAIT cells may be
caused by inflammatory cytokines, including IL-12, IL-18, IFN-α and IL-7. To explore further the possible mechanism of MAIT cell reduction in HBV-related liver failure, we quantified the plasma level of IL-7, IL-12p70, IL-18 and IFN-α. The results showed that plasma levels of IL-12 and IL-18 were increased obviously in HBV-related liver failure. Zhang et al.\(^3\) concluded that, in parallel to the reduction of MAIT cells, the increase in IL-12 and IL-18 may contribute to MAIT cell activation, loss or death. We inferred that depletion of circulating MAIT cells might be caused by stimulation by IL-12 and IL-18 in HBV-related liver failure.

In conclusion, circulating MAIT cells are decreased in HBV-related liver failure and associated with disease severity. Most importantly, circulating MAIT cells have a potential role in predicting prognosis in HBV-related liver failure patients. The mechanism of MAIT cell depletion needs to be further studied.

**ARTICLE HIGHLIGHTS**

**Research background**
Immune responses play a crucial role in the pathogenesis of liver failure. Mucosal-associated invariant T (MAIT) cells are a novel population of innate-like lymphocytes involved in inflammatory liver disease, and their potential role in liver failure remains unclear.

**Research motivation**
To determine the role of circulating MAIT cells in patients with hepatitis B virus (HBV)-related liver failure and better understand the pathophysiological mechanism of liver failure, which is helpful for clinical decision-making.

**Research objectives**
This study aimed to explore the relationship between the alteration of circulating MAIT cells and prognosis of HBV-related liver failure.

**Research methods**
Fifty-five patients with HBV-related liver failure were enrolled to assess the effect of circulating MAIT cells. Peripheral blood mononuclear cells were isolated and the expression of circulating MAIT cells was detected by flow cytometry.

**Research results**
The level of circulating MAIT cells was reduced significantly in HBV-related liver failure patients. There was also a more significant reduction of MAIT cells in patients with HBV-related liver failure compared with chronic hepatitis B patients. The alteration of circulating MAIT cells is associated with the severity and prognosis of HBV-related liver failure.

**Research conclusions**
We conclude that the circulating MAIT cells may be an important prognostic marker for HBV-related liver failure, and the lower expression of circulating MAIT cells may indicate a poor prognosis.

**Research perspectives**
The circulating MAIT cells are vital for assessing the severity and prognosis of patients with HBV-related liver failure, and the mechanism of MAIT cell depletion needs to be further studied.

**ACKNOWLEDGEMENTS**
The authors would like to thank Nantong Third People’s Hospital Affiliated to Nantong University for their technical support.
Hepatol Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1.


Xue H et al. MAIT cells in HBV-related liver failure


